After 5 years of follow-up, 34% of patients with advanced melanoma
who participated in a phase 1 clinical trial are still alive after
receiving Nivolumab treatment, a study presented at the American Academy
for Cancer Research (AACR) Annual Meeting 2016 has shown. For the study, which was initiated in 2008, researchers enrolled 107
patients who had received up to 5 prior treatments, but not Ipilimumab.
All participants received Nivolumab at 1 of 5 doses, including the
subsequently recommended dose of 3 mg/kg every 2 weeks, for up to 2
years. Results published in the Journal of Clinical Oncology in 2014 showed that some patients who achieved a response had durable responses that persisted after Nivolumab discontinuation.
Nivolumab is a human IgG4 anti-programmed death-1 monoclonal antibody
approved by the U.S. Food and Drug Administration for the treatment of
advanced melanoma, kidney cancer, and non-small cell lung cancer. It is
also being studied in patients with glioblastoma, head and neck cancer,
liver cancer, and a variety of hematologic malignancies.
No comments:
Post a Comment